Skip to content
OpenCapital
Get started

NRX Pharmaceuticals, Inc. NRXP Q3 2024 earnings

Reported November 14, 2024 · After market close

Diluted EPS-$0.15Beat by $0.66
EPS estimate-$0.81

Next report

Aug 17, 2026 (in a month)
Revenue estimate$1.7M
EPS estimate-$0.09

Versus estimates

Revenue

Q1 2026$1.1MMiss by $18.4MQ4 2025$983.0KMiss by $6.5MQ3 2025$242.0KMiss by $7.3MQ1 2025$2.3MQ4 2024$4.0KMiss by $5.0M

Diluted EPS

Q1 2026-$0.04Beat by $0.01Q4 2025$0.19Beat by $0.28Q3 2025-$0.18Miss by $0.07Q1 2025-$0.34Miss by $0.04Q4 2024-$0.30Miss by $0.10
Q3 2024-$0.15Beat by $0.66

Ask the moment NRX Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did NRX Pharmaceuticals, Inc. report Q3 2024 earnings?
NRX Pharmaceuticals, Inc. (NRXP) reported Q3 2024 earnings on November 14, 2024 after market close.
What were NRX Pharmaceuticals, Inc.'s Q3 2024 revenue and EPS?
NRX Pharmaceuticals, Inc. reported diluted EPS of $-0.15 for Q3 2024.
Did NRX Pharmaceuticals, Inc. beat estimates in Q3 2024?
EPS beat the consensus estimate of $-0.81 by $0.66.
Where can I find NRX Pharmaceuticals, Inc.'s Q3 2024 SEC filings?
You can read the 10-Q periodic report (0001437749-24-035289) directly on SEC EDGAR. The filing index links above go to sec.gov.